By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Science Briefing
  • Medicine
  • Biology
  • Engineering
  • Environment
  • More
    • Dentistry
    • Chemistry
    • Physics
    • Agriculture
    • Business
    • Computer Science
    • Energy
    • Materials Science
    • Mathematics
    • Politics
    • Social Sciences
Notification
  • Home
  • My Feed
  • SubscribeNow
  • My Interests
  • My Saves
  • History
  • SurveysNew
Personalize
Science BriefingScience Briefing
Font ResizerAa
  • Home
  • My Feed
  • SubscribeNow
  • My Interests
  • My Saves
  • History
  • SurveysNew
Search
  • Quick Access
    • Home
    • Contact Us
    • Blog Index
    • History
    • My Saves
    • My Interests
    • My Feed
  • Categories
    • Business
    • Politics
    • Medicine
    • Biology

Top Stories

Explore the latest updated news!

Ultrasound Nanoconverter Programs Immune Response in Tumor and Lymph Nodes

No directly relevant articles available this week.

A shot against decline: Shingles vaccine linked to lower dementia risk

Stay Connected

Find us on socials
248.1KFollowersLike
61.1KFollowersFollow
165KSubscribersSubscribe
Made by ThemeRuby using the Foxiz theme. Powered by WordPress

Home - Medicine - Antidepressants in Huntington’s: A surprising shield against progression

Medicine

Antidepressants in Huntington’s: A surprising shield against progression

Last updated: January 22, 2026 12:12 am
By
Science Briefing
ByScience Briefing
Science Communicator
Instant, tailored science briefings — personalized and easy to understand. Try 30 days free.
Follow:
No Comments
Share
SHARE

The latest discoveries in Neurology

A concise briefing on the most relevant research developments in your field, curated for clarity and impact.

Antidepressants in Huntington’s: A surprising shield against progression

A large-scale analysis of over 25,000 individuals with Huntington’s disease (HD) reveals a critical link between psychiatric symptoms and disease trajectory. The study found that episodes of depression and anxiety, which affect a majority of patients, are independently associated with a faster rate of disease progression and increased mortality. Crucially, when patients experiencing new depression or anxiety began antidepressant treatment, their rate of clinical decline slowed significantly and their risk of all-cause mortality dropped substantially. The research also provides preliminary evidence that different classes of antidepressants may offer specific protective benefits, such as reducing suicide risk or non-suicide related mortality.

- Advertisement -

Why it might matter to you:
This work directly challenges the concern that psychiatric medications might worsen neurodegenerative conditions, offering a paradigm where treating a comorbid symptom can modify the core disease course. For a researcher in neurodevelopmental and neurological disorders, it underscores the profound interplay between mental health and neurobiology, suggesting that therapeutic strategies must integrate psychiatric care as a potential neuroprotective intervention. It prompts a re-evaluation of how behavioral and mood symptoms are conceptualized within disease models—not just as secondary outcomes, but as active modifiers of pathological progression.


Source →


- Advertisement -
crossorigin="anonymous">

Stay curious. Stay informed — with
Science Briefing.

Always double check the original article for accuracy.

- Advertisement -


Feedback

Share This Article
Facebook Flipboard Pinterest Whatsapp Whatsapp LinkedIn Tumblr Reddit Telegram Threads Bluesky Email Copy Link Print
Share
ByScience Briefing
Science Communicator
Follow:
Instant, tailored science briefings — personalized and easy to understand. Try 30 days free.
Previous Article The Preventable Burden of Dementia
Next Article Antidepressants: A Protective Turn in Huntington’s Disease
Leave a Comment Leave a Comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related Stories

Uncover the stories that related to the post!

The Delicate Balance of Pain Relief: How a Brain LncRNA Governs Pain Sensitivity

Today’s Public Health Science Briefing | April 26th 2026, 9:00:12 am

The Enduring Shield: New Data on COVID-19 Vaccine Efficacy Against Severe Disease

A New Shield Against Respiratory Viruses in Vulnerable Populations

The metabolic cost of comfort: how obesity rewires the brain’s stress response

Time from pre‑labor rupture of membrane at term to delivery in grand multiparous women

Beyond Questionnaires: A Metabolomic Blueprint for Ultra-Processed Food Intake

The Unseen Burden: Measuring Life Quality in Overlooked Liver Syndromes

Show More

Science Briefing delivers personalized, reliable summaries of new scientific papers—tailored to your field and interests—so you can stay informed without doing the heavy reading.

Science Briefing
  • Categories:
  • Medicine
  • Biology
  • Social Sciences
  • Gastroenterology
  • Surgery
  • Natural Language Processing
  • Energy
  • Chemistry
  • Engineering
  • Neurology

Quick Links

  • My Feed
  • My Interests
  • History
  • My Saves

About US

  • Adverts
  • Our Jobs
  • Term of Use

ScienceBriefing.com, All rights reserved.

Personalize you Briefings
To Receive Instant, personalized science updates—only on the discoveries that matter to you.
Please enable JavaScript in your browser to complete this form.
Loading
Zero Spam, Cancel, Upgrade or downgrade anytime!
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?